


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-10. (canceled)

11. (previously presented) A compound of general formula (I)



and pharmaceutically acceptable salts or prodrugs thereof, wherein:

n is 0, 1 or 2;

R<sup>1</sup> and R<sup>2</sup>, independently of each other, are H, OH or OCH<sub>3</sub>;

R<sup>3</sup> is H or CH<sub>3</sub>;

R<sup>4</sup> is H, C<sub>1</sub>-C<sub>3</sub> straight or branched alkyl or, together with R<sup>3</sup>, forms a five to seven-membered carbocyclic ring;

and R<sup>5</sup> and R<sup>6</sup>, independently of each other, are H or C<sub>1</sub>-C<sub>5</sub> straight or branched alkyl

with the provisos that:

R<sup>1</sup> and R<sup>2</sup> cannot be both hydrogen;

when n is 0, R<sup>1</sup> and R<sup>2</sup> are both hydroxyl, R<sup>3</sup> and R<sup>5</sup> are hydrogen, R<sup>4</sup> cannot be CH<sub>3</sub>;

when n is 0, R<sup>3</sup> is H and R<sup>4</sup> is H or CH<sub>3</sub>, R<sup>6</sup> cannot be C<sub>1</sub>-C<sub>3</sub> straight or branched alkyl;

and that the compounds cannot be:

- 1-(4-hydroxyphenyl)-2-hydroxylaminoethane,
- 1-(4-hydroxyphenyl)-2-hydroxylaminopropane,
- 1-(4-methoxyphenyl)-2-hydroxylaminopropane,
- 1-(3,4-dimethoxyphenyl)-2-hydroxylaminopropane,
- 1-(4-methoxyphenyl)-4-hydroxylaminobutane
- 1-(3-methoxyphenyl)-2-hydroxylaminopropane,
- 1-(3,4-dimethoxyphenyl)-2-hydroxylaminoethane,
- N-methyl-1-(3,4-dihydroxyphenyl)-2-hydroxylaminopropane,
- 1-(3-methoxy-4-hydroxyphenyl)-2-hydroxylaminopropane,
- N-methyl-1-(3-methoxy-4-hydroxyphenyl)-2-hydroxylaminopropane,
- N-methyl-1-(3,4-dimethoxyphenyl)-2-hydroxylaminopropane.

12. (previously presented) A compound according to claim 11 selected from the group consisting of:

- N-(5-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-methyl-hydroxylamine;
- N-(5-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)- hydroxylamine;
- N-(5-hydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-propyl-O-ethyl-hydroxylamine;
- N-(5-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-methyl-hydroxylamine;
- N-(5-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-O-ethyl-hydroxylamine;

- N- (5-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl) -N-propyl-O-ethyl-hydroxylamine;
- N- (5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl) -O-methyl-hydroxylamine;
- N- (5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl) -O-ethyl-hydroxylamine;
- N- (5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl) -N-propyl-O-ethyl-hydroxylamine;
- N- (5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl) -N-butyl-O-ethyl-hydroxylamine;
- N- (5,6-dihydroxy-1,2,3,4-tetrahydro-naphthalen-2-yl) -N-butyl-O-propyl-hydroxylamine;
- N- (5,6-dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl) -O-methyl-hydroxylamine;
- N- (5,6-dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl) -O-ethyl-hydroxylamine;
- N- (5,6-dimethoxy-1,2,3,4-tetrahydro-naphthalen-2-yl) -N-propyl-O-ethyl-hydroxylamine;
- N- (1-methyl-2-(3-hydroxy-phenyl)-ethyl) -hydroxylamine;
- N- (1-methyl-2-(3-hydroxy-phenyl)-ethyl) -N-methyl-hydroxylamine;
- N- (1-methyl-2-(3-hydroxy-phenyl)-ethyl) -N-propyl-hydroxylamine;
- N- (1-methyl-2-(3,4-dihydroxy-phenyl)-ethyl) -N-propyl-hydroxylamine;
- N- (1-methyl-2-(3-methoxy-phenyl)-ethyl) -N-methyl-hydroxylamine;
- N- (1-methyl-2-(3-methoxy-phenyl)-ethyl) -N-propyl-hydroxylamine;
- N- (1-methyl-2-(3,4-dimethoxy-phenyl)-ethyl) -hydroxylamine;

- N-(1-methyl-2-(3,4-dimethoxy-phenyl)-ethyl)-N-propyl-hydroxylamine;
- N-(5-hydroxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-O-ethyl-hydroxylamine;
- N-(5-methoxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-O-ethyl-hydroxylamine;
- N-(5,6-dihydroxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-O-ethyl-hydroxylamine;
- N-(5,6-dimethoxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-O-ethyl-hydroxylamine;
- N-(5-hydroxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-N-propyl-O-ethyl-hydroxylamine;
- N-(5-methoxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-N-propyl-O-ethyl-hydroxylamine;
- N-(5,6-dihydroxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-N-propyl-O-ethyl-hydroxylamine;
- N-(5,6-dimethoxy-1,2,3,4-tetrahydro-2-naphthalenyl-methyl)-N-propyl-O-ethyl-hydroxylamine;
- N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-hydroxylamine;
- N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-O-ethyl-hydroxylamine;
- N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-N-methyl-hydroxylamine;
- N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-N-propyl-hydroxylamine;
- N-(2-methyl-3-(3,4-dihydroxy-phenyl)-propyl)-N-propyl-O-ethyl-hydroxylamine;
- N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-hydroxylamine;

- N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-O-ethyl-hydroxylamine;
- N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-N-methyl-hydroxylamine;
- N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-N-propyl-hydroxylamine;
- N-(2-methyl-3-(3,4-dimethoxy-phenyl)-propyl)-N-propyl-O-ethyl-hydroxylamine;  
and the pharmaceutically acceptable salts thereof.

13. (previously presented) Pharmaceutical compositions containing one or more compounds of formula (I) according to claim 11 in a mixture with suitable excipients and/or carriers.

14. (previously presented) Pharmaceutical compositions containing one or more compounds of formula (I) according to claim 11 and a compound for the treatment of central and peripheral nervous system disorders involving protein misfolding and/or misaggregation of beta-amyloid peptide, alpha-synuclein, prion protein and huntingtin selected from Alzheimer's Disease, Lewy body disease, Parkinson's Disease, spongiform encephalopathies, Huntington's Disease and systemic AA amyloidosis, in admixture with suitable excipients and/or carriers.